The startup develops a drug discovery platform that integrates human pluripotent stem cell disease models with AI-driven data generation to enhance predictive validity in early-stage drug development. By providing cost-effective insights into therapeutic targets, the platform increases the likelihood of successful drug discovery outcomes.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery processes face high failure rates and substantial costs due to the lack of predictive validity in preclinical models. The reliance on inadequate experimental models leads to poor data, ineffective target identification, and ultimately, unsuccessful therapeutic development. This results in prolonged timelines and increased financial burdens for bringing new drugs to market.
Solution
Valid aims to improve drug discovery success rates by combining human-centric, translational in-vitro models with AI-enabled data generation. The company creates complex, disease-relevant human induced pluripotent stem cell (hiPSC)-based in-vitro models designed to increase predictive validity at scale. By connecting human genetics with physiologically relevant experimental models, Valid generates meaningful "OMICs-AI data," enabling novel insights into human disease, therapeutic targets, and drug discovery. The platform moves advanced efficacy models with improved predictive validity into the earliest stages of drug discovery.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to improve the efficiency and success rates of their drug discovery programs.
Features
- Generation of disease-relevant hiPSC-based in-vitro models.
- Integration of human genetics with experimental models for enhanced physiological relevance.
- AI-enabled data generation and analysis for target discovery.
- Automated experimental platform for increased throughput and scalability.
- Production of OMICs-AI data to improve insights into human disease.